NURLF (Neural Therapeutics) Total Stockholders Equity: $0.47 Mil (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neural Therapeutics Total Stockholders Equity?

Neural Therapeutics NURLF Total Stockholders Equity is $0.47 Mil as of Jan. 2026. The stock has 1 warning sign investors should review.

Neural Therapeutics's Total Stockholders Equity for the quarter that ended in Jan. 2026 was $0.47 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Neural Therapeutics's Book Value per Share for the quarter that ended in Jan. 2026 was $0.00. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Neural Therapeutics's Debt-to-Equity for the quarter that ended in Jan. 2026 was 0.00.

Neural Therapeutics  (OTCPK:NURLF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Neural Therapeutics's Book Value per Share for the quarter that ended in Jan. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(0.474-0)/157.396
=0.00

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Neural Therapeutics's Debt-to-Equity for the quarter that ended in Jan. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 0.474
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neural Therapeutics Total Stockholders Equity Related Terms

Neural Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Neural Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neural Therapeutics Total Stockholders Equity Chart

Neural Therapeutics Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Total Stockholders Equity
Get a 7-Day Free Trial 0.77 -0.01 -0.20 -0.50 -0.53

Neural Therapeutics Quarterly Data
Jul20 Jul21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.31 -0.42 -0.53 0.75 0.47
What does a Total Stockholders Equity of $0.47 Mil mean?
Neural Therapeutics (NURLF) has a Total Stockholders Equity of $0.47 Mil as of Jan. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Neural Therapeutics and its competitors.
Is Neural Therapeutics' Total Stockholders Equity too high?
Neural Therapeutics' current Total Stockholders Equity is $0.47 Mil.
How does Neural Therapeutics' Total Stockholders Equity compare to VRTX and REGN?
Neural Therapeutics' Total Stockholders Equity of $0.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Neural Therapeutics and its competitors. Neural Therapeutics's current Total Stockholders Equity is $0.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (NURLF) has a current Total Stockholders Equity of $0.47 Mil. The current Total Stockholders Equity is $0.47 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Neural Therapeutics (NURLF), the current Total Stockholders Equity is $0.47 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neural Therapeutics Business Description

Other Exchanges M6B:GermanyNURL:Canada
Address 1-130 Adelaide Street West, Suite 3002, Toronto, ON, CAN, M5H 3P5
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.